1. Home
  2. RGT vs MXCT Comparison

RGT vs MXCT Comparison

Compare RGT & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Global Value Trust Inc.

RGT

Royce Global Value Trust Inc.

N/A

Current Price

$14.32

Market Cap

94.4M

Sector

Finance

ML Signal

N/A

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.03

Market Cap

93.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGT
MXCT
Founded
1986
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.4M
93.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RGT
MXCT
Price
$14.32
$1.03
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
12.6K
1.0M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
1.43%
N/A
EPS Growth
N/A
N/A
EPS
0.92
N/A
Revenue
N/A
$33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.50
P/E Ratio
$15.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.40
$0.64
52 Week High
$14.99
$2.40

Technical Indicators

Market Signals
Indicator
RGT
MXCT
Relative Strength Index (RSI) 52.26 60.44
Support Level $12.50 $0.77
Resistance Level $14.68 $1.16
Average True Range (ATR) 0.19 0.07
MACD -0.04 0.01
Stochastic Oscillator 48.32 64.10

Price Performance

Historical Comparison
RGT
MXCT

About RGT Royce Global Value Trust Inc.

Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: